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Body/Summary of Findings: Our lab and others have accumulated evidence that the myelodysplastic syndromes (MDS) are a disorder arising in hematopoietic stem cells (HSC), demonstrating the presence of disease specific cytogenetic abnormalities and distinct gene expression programs in purified HSC's (Lin   -CD34 + CD38 -CD90 + CD45RA -) from MDS patients. [1] [2] [3] [4] [5] We previously assessed HSC's from five MDS bone marrow (BM) samples by FISH for cytogenetic abnormalities previously identified in each patient. In each of the samples tested, the previously identified chromosomal aberration was present within the HSC population at high frequencies (>84%, data presented in original submission). We have now demonstrated that FACSpurified MDS HSC's can engraft irradiated immunodeficient NOD/SCID/IL2-R null mice (NSG) pup recipients and that the engrafted human cells contain previously characterized cytogenetic lesions. These studies confirm that the HSC is the disease-initiating cell in MDS.
Aberrantly expressed miRNA's have been identified in nearly all hematopoietic malignancies, where they function as oncogenes or tumor suppressors. 7 In MDS, there is evidence that miR-145 and miR-146a contribute to the phenotype of the 5q-syndrome, possibly through inappropriate activation of innate immune signaling. 8, 9 Five recent studies have evaluated miRNA expression in non-5q-MDS, identifying dysregulation of a number of miRNA's, including miR-150, miR-181a, miR-221, and miR-222, as well as a ten miRNA signature with prognostic significance. [10] [11] [12] [13] [14] Despite these intriguing data, there is no functional data to support a direct pathogenic role for any of these miRNA's in MDS. Furthermore, a, major limitation of these studies to better understanding the role of miRNA's in MDS HSC's was the use of non-purified BM cell populations for analysis. In the past year, two reports have described miRNA expression profiles in CD34 + BM cells from MDS patients, 15, 16 finding marked upregulation of the P53 target miR-34a in low risk and 5q-MDS, a new finding that may help explain the increased apoptosis that characterizes MDS. This demonstrates the potential of working with purified cell populations to unmask novel findings. However, even CD34 + selected BM cells represent a highly heterogeneous population composed predominantly of committed hematopoietic progenitors. 17 Because working with heterogeneous cell populations may obscure the true changes that underlie the MDS phenotype at the level of the HSC, we have proposed to evaluated highly purified cells from the lin -CD34 + CD38 -CD90 + CD45RA -fraction of bone marrow, which I previously showed to be highly enriched for human HSC's. 18 We have made significant progress with respect to each of our Specific Aims. These results will be discussed as they were presented in our original SOW.
STATEMENT OF WORK
Task/Aim 1: To determine the functional role of microRNA's in MDS HSC. 1a. Regulatory review and approval process for animal studies. We have successfully obtained regulatory approval for our animal studies. Currently, our 3-yr renewal protocol has been submitted and is pending approval.
1b. To characterize the in vitro and in vivo functional properties of normal and MDS HSC. Update: We have developed both in vitro and in vivo assays to assess MDS HSC function. FACS-sorted MDS HSC do not form significant numbers of colonies ( Figure 1 ). Nevertheless, we have been able to characterize several aspects of MDS HSC biology by flow cytometry: 1) MDS HSC cycle more than normal young HSC, but not more than age-matched controls (Figure 2 ) 2) MDS HSC do not exhibit increased apoptosis compared to age-matched normal controls, but MDS myeloid progenitors do ( Figure 3 ). 3) MDS bone marrows exhibit significantly reduced frequencies of GMP (Figure 4 ). Therefore, we established a xenotransplantation system in which FACS-purified human HSC's are transplanted into newborn immunodeficient NOD/SCID/IL2-R null mice (NSG). We previously reported that using this assay, successful long-term engraftment (>12 weeks) with lympho-myeloid human grafts has been established using as few as 1000 normal HSC's, 1000 HSC's from low-risk MDS, and 2500 HSC's from RAEB-2 MDS (data not shown). We have now gained significant additional experience using this system to characterize basic properties of MDS HSC. When MDS HSC's were transplanted into sublethally irradiated NOD/SCID/IL2Rgamma null (NSG) mice, we were able to establish long-term grafts ( Figure 5) . In order to demonstrate that the engrafting cells were derived from the transplanted HSC, in cases in which a karyotypic abnormality had been identified, we performed FISH on FACS-sorted cells from engrafted mice. In both cases in which a karyotypic abnormality had been identified, we were able to show that the engrafted HSC harbored the original cytogenetic abnormality ( Figure 5 ). In addition, engrafted committed progenitors exhibited an altered composition with a decrease in the number of immunophenotypically defined GMP ( Figure 6 ). In addition, grafts initiated by MDS HSC were composed almost entirely of myeloid lineage cells with few B-cells produced ( Figure 6 ). While we have not yet achieved engraftment of the originally planned number of samples, we are currently working to expand sample numbers.
1c. To identify differentially expressed miRNA's in MDS HSC compared to normal HSC. Update:
We recently reported a transcriptome analysis of HSC's from eight low-risk MDS patients (refractory anemia, [RA]) with normal cytogenetics and 10 normal controls 20 . This revealed dysregulation of 3,258 mRNAs (FDR <0.1) in MDS, including downregulation of many ribosomal proteins ( Figure 7 ). Among these was RPS6 (40-45% reduction in 8/8 patients), with our subsequent studies demonstrating that shRNA knockdown of RPS6 in human cord blood CD34
+ cells leads to a block in erythroid differentiation and disrupts polysomes (Figure 8 ) 20 . These findings suggest that ribosomal protein insufficiency, previously implicated by Ebert and colleagues in 5q-MDS, 21 may also be a general feature of non-5q-MDS. These compelling findings demonstrate the power of working with purified HSC populations, suggesting that an analysis of miRNA expression in purified HSC's will lead to similarly new insights into MDS biology.
Using the same FACS-purified MDS HSC samples for which we have generated mRNA transcriptome data, we have now begun to generate miRNA expression profiling data using our previously established TaqMan-based qRT-PCR protocol 22 .
Comparisons of miRNA expression profiles has been made to agematched controls, as we have shown that many mRNA transcriptomal changes identified in MDS HSC are not specific to MDS and are instead age-related changes (data not shown). In a preliminary analysis of miRNA expression profiles from HSC's purified from six low-rsk MDS patients (RA) with normal cytogenetics and three normal, age-matched elderly controls, we identified 31 significantly dysregulated miRNA's (FDR <0.1) in MDS HSC's ( Figure 9 ). Among the significantly downregulated miRNA's was miR-125b (mean 171-fold decrease) but not miR-125a. We have previously demonstrated that miR-125b regulates HSC survival through an antiapoptotic mechanism, leading to a preferential expansion of lymphoid-biased HSC because of their intrinsically higher baseline levels of apoptosis. 23 We propose that downregulation of miR-125b in the MDS HSC contributes to the increased apoptosis that characterizes the MDS BM. Furthermore, preferential apoptosis in lymphoid biased HSC's may explain why the cytogenetic abnormalities, tri-lineage dysplasia, and ineffective hematopoiesis that characterize MDS are not generally found in the lymphoid compartment. 1d. To test the ability of candidate MDS miRNA's to induce MDS-like changes in normal human HSC or rescue MDS HSC. Update: In preliminary experiments, we have demonstrated that overexpression of an anti-sense "miRZIP" directed towards miR-125b in mouse HSC's in vitro leads to increased apoptosis and decreased cellular output, as well as dysplastic maturation of granulocytes ( Figure. 10 ), similar to the phenotype observed in MDS patients. Other miRNA's of interest downregulated in our data set include miR-146a, 8 whose haploinsufficiency appears to contribute to the pathogenesis of the 5q-syndrome by activation of the innate immune system (and interestingly is also downregulated in our cohort of non-5q-patients), and miR-328, which promotes the translation of the myeloid lineage transcription factor CEBPα. 27 In an analysis comparing common myeloid progenitors from four MDS patients with four normal controls, we did not observe dysregulation of miR-125b, miR-146a, and miR-328, suggesting that the pathogenic significance of these miRNA's is specific to the disease initiating HSC in MDS. We are currently in the process of measuring miRNA expression in HSC purified from RPS6 mutant mice; therefore, we have not performed functional experiments proposed in our original proposal. We have, nonetheless, established methods to efficiently introduce lentivirally expressed shRNA's to Rp transcripts into primary cells, demonstrating that human HSC's can be lentivirally transduced with 60-90% efficiency (data not shown). HSC from RPS6 hemizygous mice as well as heterozygous RPS19 missense mutants 28 have been FACS-purified from 3-5 mice and these RNA's are in the process of being prepared for miRNA and mRNA expression profiling studies.
2c: To test candidate MDS miRNA's for enhancement/abrogation of the MDS phenotype in HSC from human or mouse HSC with known ribosomal deficiencies. Update: Given our initial miRNA expression profiling results identifying miR-125b as a markedly downregulated miRNA in MDS HSC, we will first test whether ectopic miR-125b expression can rescue the MDS HSC phenotype by lentivirally transducing primary MDS HSC with miR-125b. In addition, we have obtained the MDS92 and MDS92L cell lines, which harbor -5q abnormalities in addition to a complex karyotype 29 . While MDS92 cells differentiate spontaneously in the presence of cytokines, thereby mimicking MDS, the MDS92L cell line is maturation arrested and is more similar to transformed AML. Both cell lines offer an alternative system to test the ability of ectopically expressed miRNA's such as miR-125b and miR-145 to rescue aspects of the MDS phenotype, including cell cycling, apoptosis, presence of dysplasia, and decreased erythroid maturation. 2d: To determine whether miRNA induction or reversal of miRNA-like phenotypes in HSC is associated with altered ribosomal protein function. Update: We have successfully established the ability to generate polyribosome profiles using standard sucrose gradient centrifugation techniques (Figure 8 ). Using a 10-50% sucrose step gradient, we have been able to generate ribosomal profiles from as few as 50,000 cells (data not shown). Following transduction of miR-125b, miR-145 and empty control lentiviruses into MDS92, MDS92L, or primary MDS cells, we will perform ribosomal profiling as described. KU812 cells were transduced with a len3virus expressing an shRNA against Rps6. Three days later, the GFP+ transduced cells were FACS--sorted and polysome profiles were generated using a standard 10--50% sucrose gradient.
Milestones
MDS OLD YOUNG P < 0.05 We and others have shown that the binding of cell surface calreticulin (CRT) on a target cell to the low--density lipoprotein--related protein (LRP1) receptor on macrophages is an important mechanism for the phagocytosis of target cells, including apoptotic cells and cancer cells, including AML (18--20) . We have also shown that the concomitant up--regulation of anti--phagocytic CD47 on the surface of cancer cells is critical for their evasion of immunosurveillance (18) . In addition, blocking CD47 ligation of its receptor SIRPα allows for the pro--phagocytic cell surface CRT to signal phagocytosis and clearance of tumor cells (18) . While cell surface CD47 expression is increased in numerous tumor types, including AML(21--24), these molecules have not been well characterized in MDS.
AML is a multistep disease in which the self--renewing leukemia stem cells (LSCs) emerge at a multilineage progenitor stage. In hematopoiesis, only HSCs self--renew, and therefore we proposed (25--28) and in several cases have shown that the accumulation of genetic and epigenetic changes characteristic of leukemia progression occur in clones of self--renewing HSCs, and not in the downstream progeny that cannot normally self--renew (29--33) . It is likely that at least some events in pre--leukemic progression trigger both programmed cell death and programmed cell removal (28) . Here we test the notion that low risk MDS (including refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and myelodysplastic syndrome not otherwise specified but with fewer than 5% blasts) follow this progression toward high risk MDS (refractory anemia with excess blasts; RAEB, including both WHO RAEB--1 and RAEB--2 subtypes), and reveal a stage wherein the pre--leukemic HSC clones outcompete normal HSC clones, but, at their oligolineage progenitor stage, lose blood--forming capacity as a result of programmed cell death and/or programmed cell removal.
In this study, we demonstrate that low risk MDS HSCs (from bone marrow samples from patients with refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and myelodysplastic syndrome not otherwise specified but with fewer than 5% blasts) can transplant the clonal disease into immunodeficient mice. We also show that fewer granulocyte--macrophage progenitors (GMPs) are present in low risk MDS bone marrow compared to normal and non--MDS bone marrow samples, a quantitative finding that can be used to aid diagnosis of MDS in the clinical setting. This reduction in GMPs is likely secondary to increased programmed cell death and programmed cell removal by macrophages, the latter of which is due to up--regulation of CRT. In high risk refractory anemia with excess blasts (RAEB) stage of MDS, the frequency of GMPs in the bone marrow is higher than in low risk MDS, likely due to their evasion of phagocytosis by up--regulation of CD47.
Results

Similar frequency of HSCs in low risk MDS bone marrow and normal bone marrow
MDS is thought to be a disease of HSCs, leading to variable cytopenias due to ineffective production of mature granulocyte, erythroid, and/or megakaryocyte (platelet) populations(1). However, there is little information regarding the status of the most primitive hematopoietic stem and progenitor compartments in MDS bone marrow. We (elderly), non--anemic normal controls. We found that the frequencies of these cells were not significantly higher in low risk MDS bone marrow than in normal bone marrow ( Figure   1a ). These findings suggest that MDS HSCs expand at the expense of normal HSCs.
HSCs from MDS bone marrow can transplant clonal disease into immunodeficient mice
Previously, it has been shown that the HSC compartment in MDS is enriched for cytogenetically abnormal cells, including in two MDS samples with monosomy 7(9, 10, 12).
We have evaluated three MDS samples harboring a clonal monosomy 7 cytogenetic abnormality. Consistent with previous reports, we can detect this cytogenetic abnormality by FISH in greater than 95% of the cells within the immunophenotypically defined HSC population (Figure 1b) . We then purified the HSCs by FACS and xeno--transplanted them into sublethally irradiated immunodeficient NOD.Cg--Prkdc scid Il2rg tm1Wjl /SzJ (NSG) pups (40) . NSG mice transplanted with MDS HSC were sacrificed at 12--16 weeks and human chimerism was measured by the presence of human CD45+ cells in the bone marrow of all the recipient mice and expressed as human chimerism per 500 HSCs transplanted ( Figure   1c ). Human CD45+ cells were then FACS--purified from these engrafted mice and analyzed by FISH. We find that the human CD45+ cells from these engrafted mice harbor the cytogenetic abnormality (Figure 1d (12) . We found that low risk MDS bone marrow exhibits alterations in myeloid progenitor distribution, with significant reduction of GMP frequency in low risk MDS compared to normal controls (p<10 --13 ) as well as non--MDS patients exhibiting at least one cytopenia (p<10 --10 ) (Figure 2a, b) . When the frequency of GMPs as a percentage total of myeloid progenitors (GMP/[CMP+GMP+MEP]) was calculated, it was decreased by an average of 2.6--fold (Figure 2b ) and was accompanied by concomitant increases in relative CMP frequency compared to non--MDS controls (Supplemental Figure 1a) . Interestingly, the loss of GMPs in low risk MDS bone marrow was not regularly accompanied by absolute neutropenia in the peripheral blood. Notably, the most common cytopenia in MDS is anemia, but we found that MDS MEPs are not significantly reduced in frequency relative to the total myeloid progenitor population (Supplemental Figure 1b) . We do not yet have markers that define pure megakaryocytic or pure erythroid committed progenitors, and although we suspect these will be altered in the marrow of MDS patients with respective thrombocytopenias and anemias, we cannot test that hypothesis directly at this time.
Accurate absolute quantification of HSC and progenitor numbers from human bone marrow samples is challenging due to the inherent variability in bone marrow aspiration technique, which always collects a varying proportion of cells from the peripheral blood.
Therefore, to better approximate absolute numbers of myeloid progenitor subsets in the bone marrow, we compared frequencies of CMPs, GMPs, and MEPs within the lineage--negative population, which are more likely to reflect hematopoietic cells from the bone marrow than total cells collected from bone marrow aspiration. We found that low risk MDS GMPs are decreased in frequency, on average by 3.0--fold, within the lineage--negative population compared to normal (p<0.0006) (Figure 2c ), whereas low risk MDS CMPs and MEPs are not increased in frequency within the lineage--negative population (Supplemental Figure 1c, d) , suggesting that one of the defects in MDS hematopoiesis is not due to an absolute expansion of the CMP or MEP populations, but a significant absolute reduction in the GMP population.
GMP--to--myeloid progenitor ratios predictive of low risk MDS
Because we observed a consistent, statistically significant decrease in the frequency of GMPs among total myeloid progenitors, we tested whether or not GMP frequency could be used as a clinically useful tool to diagnose low risk MDS. Using the gating strategy depicted in Figure 2a , we determined the frequencies of GMPs, CMPs, and MEPs for MDS patients and normal controls. Setting a threshold of 24.0% frequency of GMPs among the myeloid progenitors yielded a sensitivity of 92% and a specificity of 89% for correctly identifying low risk MDS patients. The reduced GMP frequency observed in low risk MDS was rarely seen in bone marrow samples from non--MDS bone marrow disorders. We evaluated, after determination of our initial threshold of 24.0% GMPs for low risk MDS diagnosis, the myeloid progenitor profile of 40 consecutive bone marrow samples submitted for evaluation of MDS and correctly categorized 100.0% of 28 non--MDS samples (false positive rate of 0.0) and 83.3% of 12 low risk MDS samples in a blinded fashion (false negative rate of 0.067).
While many diagnostic flow cytometry labs are beginning to employ 6--color flow cytometry into their clinical practice, many laboratories still do not possess the ability to evaluate more than 4 colors simultaneously. Because identification of myeloid progenitors typically requires at least 5 colors (Lin, CD34, CD38, CD123, CD45RA), we re--evaluated the same flow cytometry data files using only 4 colors to identify "pseudo--" or "surrogate" GMP (CD34+, CD38+, CD123+, CD45RA+), CMP, and MEP populations. Unfortunately, using this strategy, attempting to gate on myeloid progenitors without performing a pre--gate on Lin--cells did not result in statistically significant differences in low risk MDS and non--MDS samples, possibly due to the variable inclusion of peripheral blood cells retrieved during bone marrow aspiration.
Decreased frequency of GMPs is an intrinsic characteristic encoded within low risk
MDS HSCs
To further determine whether the decreased frequency of GMPs is an inherent feature of low risk MDS, we transplanted FACS--purified HSCs from low risk MDS bone marrow samples into sublethally irradiated NSG pups, and analyzed the distribution of myeloid progenitors in the bone marrow of engrafted mice. As controls, we transplanted (Figure 3c ). These data indicate that the low risk MDS HSCs can transfer a human graft that recapitulates features present in MDS patient bone marrow samples. Furthermore, it suggests that the relative loss of GMP is due to a cell--intrinsic defect in MDS HSCs.
Apoptosis of low risk MDS progenitor cells but not hematopoietic stem cells
Numerous prior studies characterizing CD34+ cells, of which only a small fraction are putative HSCs, in the bone marrow of MDS patients revealed two hallmarks of MDSincreased apoptosis and a concomitant increased in the proliferative fraction; however, these data provide no specific information regarding whether or not HSCs or specific 
Increased calreticulin expression in low risk MDS progenitor cells
In addition to increased apoptosis, another mechanism that may contribute to the reduced frequency of GMPs observed in low risk MDS patients is increased phagocytosis.
Therefore, we measured the cell surface expression of the pro--phagocytic marker CRT in normal and low risk MDS bone marrow. When we examine the HSC population, we find that cell surface expression of CRT is similar between normal and low risk MDS HSCs (Figure 5a ). In contrast, we found that cell surface expression of CRT is on average 2. 
CD34+CD38+ progenitor cells from RAEB MDS express increased CD47 compared to low risk MDS CD34+CD38+ progenitor cells
Given that CD47 is an anti--phagocytic marker that counterbalances the pro--phagocytic signal from cell surface CRT, we investigated the expression of CD47 on CD34+CD38+ progenitors from low risk MDS as well as high risk MDS (RAEB). Of note, the immunophenotypic GMP population is not reduced in RAEB, and this population is predominantly composed of blasts (Supplemental Figure 4a) . We first measured the cell surface expression of CD47 on low risk MDS CD34+CD38+ progenitors and found that CD47 expression is not significantly increased compared to normal CD34+CD38+
progenitors (Supplemental Figure 4b) . We also investigated CD47 expression on low risk MDS CMPs, GMPs, and MEPs, and found that CD47 expression in these populations is similar in low risk MDS compared to their normal counterparts (Supplemental Figure 4c) .
However, when bone marrow samples from patients with high risk MDS (RAEB) were evaluated, CD34+CD38+ progenitors were found to express an average 3.6--fold increase in CD47 compared to this same immunophenotypic population in low risk MDS and normal bone marrow samples (p<0.03) (Figure 6a) . Moreover, the blasts within the CD34+CD38+ population from RAEB exhibit significantly increased expression of CD47 (p<0.03) ( Figure   6b ). Of note, CD34+CD38+ cells from RAEB also express increased cell surface CRT compared to normal CD34+CD38+ cells (p<0.04) (Figure 6c ), and it is the blast population that has significantly higher expression of cell surface CRT (p<0.04) (Figure 6d ).
These observations lead us to hypothesize that CD34+CD38+ cells from RAEB are The importance of macrophage--mediated phagocytosis in MDS pathogenesis is further supported by our finding that that CD34+CD38+ hematopoietic progenitor cells from high risk MDS (RAEB) bone marrow samples express increased CD47, a cell surface marker we and others have shown is a critical anti--phagocytic marker that counteracts the pro--phagocytic cell surface CRT signal (18--24) . In this study, we have shown that low risk MDS progenitor cells express increased levels of cell surface CRT but not CD47, compared to normal controls, and are therefore susceptible to phagocytosis and clearance by macrophages. In contrast, MDS variants that have progressed to RAEB express high levels of CD47, and can avoid phagocytosis, likely promoting their ability to propagate, and gradually take over the bone marrow. We propose that up--regulation of CD47 is an important step in the transformation of low risk MDS into RAEB and possibly AML.
In summary, we propose that the events that characterize the early stages of MDS result from MDS HSCs expanding in competition with normal HSC, yet losing oligolineage progenitors by programmed cell death and/or programmed cell removal and resulting in peripheral cytopenias. These data provide an explanation as to why do so many different mutations, translocations, and likely epigenetic alterations can give rise to MDS; these genetic and epigenetic insults ultimately up--regulate programmed cell death and programmed cell removal (28, 42) . We propose that as the MDS clones lose programmed cell death, the cytopenias still result from programmed cell removal. Finally, in the late stages of progression resulting in RAEB and AML, there is the loss of programmed cell removal by expression of the "don't eat me signal," CD47. 
Materials and Methods
Human Samples.
Human bone marrow samples were collected from the Stanford Department of Pathology, according to an IRB--approved protocol. Samples were selected from submitted cases solely based on the ability of investigators to obtain and freeze the samples within 72 hours post--collection. The patient samples represented the full spectrum of WHO subtypes of low risk MDS without excess blasts (n=46; includes refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and myelodysplastic syndrome not otherwise specified but with fewer than 5% blasts) and high risk MDS (n=7; refractory anemia with excess blasts, includes both WHO RAEB--1 and RAEB--2 subtypes). newborn pups were pre--conditioned with 100 rads of gamma irradiation 4--24 hours prior to transplantation (8, 40, 43) . Cells resuspended in PBS containing 2% FCS were transplanted intravenously via the anterior facial vein using a 30 or 31 gauge needle.
Controls included a group of non--MDS
Analysis of Human Chimerism
The 
Macrophage Isolation and Culture
Leukocyte--enriched human peripheral blood was obtained from the Stanford Blood Center.
Mononuclear cells were isolated using Ficoll--Paque (GE HLS) and plated in IMDM+10%
human serum (R&D) with PenStrep and Glutamax for 6--day incubation. Peripheral blood derived macrophages are an adherent population following 7--day incubation.
In Vitro Phagocytosis Assay
Human peripheral blood--derived macrophages were harvested by incubation in 10% EDTA (GIBCO) for 30 minutes at 4 degrees and gentle scraping. Macrophages were plated at 5 × 
Statistical Analysis.
Statistical analysis using Student's t--test and calculations of specificity and sensitivity were done using Microsoft Excel and/or GraphPad Prism (San Diego, CA) software.
